Page 853 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 831

Myeloma-related disorders (Continued) Needle biopsy tract, 159 Neuroglycopenia, 583
solitary and extramedullary plasmacytic Needle core biopsy Neurologic manifestation, of cancer, 106
myasthenia gravis, 99b, 106
tumors, 749–752, 749f–750f
image guidance and, 159
VetBooks.ir diagnosis, 750–751 indications/procedure for, 159 Neuronal death, pain management and,
peripheral neuropathy, 99b, 106
instruments for, 159
history and clinical signs, 750
pathology and natural behavior, 750 needles, 159 298–299
prognosis, 751–752 mechanisms for action for, 159f Neurotoxin, pain management and, 298–299
therapy, 751 Neoadjuvant chemotherapy, 170 Neutering/spaying, 92–93
Myelophthisis, 104 primary, 183 osteosarcoma and, 92
Myeloproliferative disease, 23 Neoplasia prostate cancer and, 92
FIV infection and, 25 Cori cycle hypothesis of, 300 Neutron, 210–211
Myeloproliferative neoplasms, canine, definition of, 62 Neutrophil nadir, 189f
734–735 feline leukemia virus and, 93 Neutrophilic leukocytosis, tumors associated
basophilic and eosinophilic leukemia, 735 grading and staging of, 67–69 with, 99b, 103
chronic myelogenous leukemia, 734–735 of the heart, 787 New drug applications (NDAs), 345
treatment, 739 comparative aspects, 791 Next generation sequencing, 151
essential thrombocythemia, 735 diagnostic techniques and workup, Nitrogen mustard, 182
treatment, 739 788–790, 789f–790f chlorambucil, 191
polycythemia vera, 734 history and clinical signs, 788, 788t cyclophosphamide, 190–191
treatment, 739 incidence and risk factors, 787 ifosfamide, 191
Myxoma sarcomas, 553 pathology and natural behavior, 787–788 mechlorethamine, 190
Myxosarcoma, 405t, 406 prognosis, 791 melphalan, 190
fine-needle aspiration of, 137f–138f therapy, 790–791 Nitrosourea
histochemical stains for, 71 histologic features of, 63–67, 65t lomustine as, 191
MZL. see Marginal zone lymphoma lymph node metastasis, 66–67 streptozotocin as, 191–192
mitotic figures, 65–66, 66t NMDA. see N-methyl-D-aspartate antagonist
N management of, 61 NME. see Necrolytic migratory erythema
Naked DNA delivery, 251–253, 252t of the nipple, malignant canine mammary N-methyl-D-aspartate antagonist (NMDA),
safety considerations for, 257 neoplasms, 609 central sensitization and, 295
Naked DNA virus, 19–20 p53 and, 44 No observable adverse event level (NOAEL),
Nasal adenocarcinoma, cell characteristics in, pathology of, 61–80 341
136 radiation-induced, 212 NOD-like receptor agonists, 237
Nasal carcinoma, 136 Neoplasm, 62 Nodular dermatofibrosis
Nasal cavity, tumors of, 494–503 Neoplastic cell, propagation of, 300 tumors associated with, 99b
comparative aspects of, 504–505 Neoplastic chromaffin cells, 573 view of, 105f
larynx and trachea, cancer of, 505 Neoplastic disease, FeLV causing, 23–24 Nodular fasciitis, 404–406
Nasal embolization, 178–179 Neoplastic populations, description of, 130–131 Nonfunctional pituitary tumors, 565
Nasal planum, cancer of, 492 Neoplastic transformation Non-Hodgkin’s lymphoma, smoking
anatomy in, 492 cause of, 352 and, 14
diagnostic evaluation for, 492 pathway specific drugs for, 354 Noninductive odontogenic tumor, 447
pathology, behavior, and history for, 492 Nephrectomy, 652 Noninvasive transitional cell carcinoma
treatment for, 492–494 Nephroblastoma, 652, 666t (TCC), 236
chemotherapy in, 494 Nerve sheath tumor, cell characteristics in, 138 Nonlymphoid hematopoietic neoplasia, 23
external beam radiation therapy for, Nervous system tumors, 657–674 Nonlymphoid neoplasms, clonality,
493–494 classification of, 657 assessment of, 151
photodynamic therapy in, 494 cranial, paraspinal, and peripheral nerves Nonproliferating cell, 36
strontium plesiotherapy in, 494, 494f tumors, 669–670 Nonspecific immune activation, to generate
surgery in, 492–493, 493f grading of, 657 antitumor activity using biological
Nasal planum tumor, treatment of, 357 intracranial tumors, 657–665 response modifiers, 236–237
Nasal tumors, biopsy of, 498f spinal cord tumors, 666–669 Nonsteroidal antiinflammatory drug (NSAID)
Nasogastric tube, 304–305 Neural astrocytic tumor, 72t–73t amantadine and, 296
Nasopharyngeal carcinoma, 26 Neurobiologic signature, of pain, 297 for pain management, 290–295
Natural killer cell immunotherapy, 242 Neuroblastoma cell, 50 Nonverbal behavior, demonstrating, 315
NCI60 human tumor cell line panel, 183–184 Neuroendocrine carcinoma, 360 Nonviral gene delivery, 251–253, 252f
NDAs. see New drug applications Neuroendocrine tumors Nonviral vector, 252t
Necrolytic migratory erythema (NME), 585 characteristics of, 136 Normoxic cell, 210
characteristics of, 105 histochemical stains for, 71t Norwegian Canine Cancer Registry, 83t
tumors associated with, 99b immunohistochemical markers/panels for, Notch-HES1 signaling pathways, canine
Necrosis 72t–73t osteosarcoma and, 526–527
characteristics of, 39 pathology and natural behavior of, 456 Notoginseng, 334–335
process of, 6 sites for, 136 Novel combinations, drug therapies for
role of, 46 therapy and prognosis for, 459 cancer, 198